Abstract: Silicon-based tetrahydrocannabinol derivatives and methods for their synthesis are provided, in which the derivatives contain a tetrahydrocannabinol molecule and at least one silicon-based group containing Si—O—Si bonds. The derivatives are useful in topical and dermatological compositions, have potential beneficial topical properties, and enhance solubility and compatibility in topical and dermatological formulations containing the silicon-based materials.
Type:
Grant
Filed:
December 10, 2020
Date of Patent:
June 6, 2023
Assignee:
GELEST, INC.
Inventors:
Barry C. Arkles, Taewoo Min, Jonathan D. Goff
Abstract: Pharmaceutical compositions and methods of their use are provided for reducing inflammation in a subject, blocking leukocyte recruitment, inhibiting tumor metastasis, treating sepsis and preventing/reducing acute kidney injury.
Type:
Grant
Filed:
July 8, 2019
Date of Patent:
June 6, 2023
Assignee:
Arch Biopartners, Inc.
Inventors:
Stephen Mark Robbins, Donna Lorraine Senger, Jennifer Joy Rahn, Arthur Wing Sze Lau, Daniel Abraham Muruve, Saurav Roy Choudhury, Liane Babes, Paul Kubes
Abstract: The present invention relates to a method for increasing the blood-brain barrier permeability, and more particularly, to a method for increasing the blood-brain barrier permeability, the method including: (S1) a step of delivering a nanogenerator carrying a nitric oxide (NO) donor to a site adjacent to the blood-brain barrier; (S2) a step of delivering a first triggering stimulus to an area where the nanogenerator has been delivered so as to release nitric oxide from the nanogenerator; and (S3) a step of allowing the released nitric oxide to activate matrix metallopeptidase-9 (MMP-9) and inducing the activated MMP-9 to weaken the tight junction between a cerebrovascular endothelial cell and another cerebrovascular endothelial cell.
Type:
Grant
Filed:
March 11, 2021
Date of Patent:
May 30, 2023
Assignee:
POSTECH RESEARCH AND BUSINESS DEVELOPMENT FOUNDATION
Abstract: The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.
Type:
Grant
Filed:
September 23, 2022
Date of Patent:
May 30, 2023
Assignee:
AbbVie Inc.
Inventors:
Ayman Allian, Fredrik Lars Nordstrom, Ahmad Y. Sheikh, Thomas B. Borchardt
Abstract: The invention relates to a process for producing ethylene glycol and/or ethylene carbonate, said process comprising contacting at least a portion of a recycle gas stream comprising an alkyl iodide impurity with a guard bed system positioned upstream of an ethylene oxide reactor to produce a treated recycle gas stream, wherein the guard bed system comprises silver on alumina; contacting a feed gas stream comprising ethylene, oxygen and at least a portion of the treated recycle gas stream with an epoxidation catalyst in the ethylene oxide reactor to produce an epoxidation reaction product comprising ethylene oxide; and contacting at least a portion of the epoxidation reaction product comprising ethylene oxide with an aqueous absorbent in the presence of an iodide-containing catalyst in an absorber to produce an aqueous product stream comprising ethylene carbonate and/or ethylene glycol and the recycle gas stream comprising the alkyl iodide impurity.
Type:
Grant
Filed:
December 6, 2018
Date of Patent:
May 23, 2023
Assignee:
SHELL USA, INC.
Inventors:
Roel Guillaume Hubertus Leonardus Bastings, Jesse Raymond Black, Vesna Bojovic, Wayne Errol Evans
Abstract: The present invention relates to a composition comprising a) at least one oil phase, b) at least one aqueous phase, c) at-least one emulsifier, wherein the at-least one emulsifier is any or combination of at-least one emulsifier agent, water with emulsification properties, oil with emulsification properties, and active ingredient with emulsification properties; and d) optionally, one or more biologically active ingredients. The present invention also relates to use of the composition for personal care, pet care, home care, deodorants, pesticides, moisturizers, disinfectants, cleansers, therapeutic devices, topical supplements and/or nutrition. The present invention also relates to a method for preparing such a composition.
Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI and formula XII and, the methods for the treatment of oral infectious diseases may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of oral infectious diseases.
Abstract: Disclosed herein is a ready-to-use liquid, injectable formulation comprising lidocaine and epinephrine. Also disclosed herein is a process for preparing a ready-to-use liquid formulation comprising lidocaine and epinephrine, as well as methods for using the ready-to-use liquid formulation.
Type:
Grant
Filed:
January 13, 2021
Date of Patent:
May 9, 2023
Assignee:
QUVA PHARMA, INC.
Inventors:
Travis A. Leeah, Jianping Chen, Lijie Zhao
Abstract: The subject invention provides catalytical compounds/complexes, compositions comprising such compound/complex, synthesis of the compounds/complexes, and methods of using such compounds/complexes as catalysts in, for example, RCM reactions. Specifically, the subject invention provides the synthesis of the first catalytically active V oxo alkylidene, VO(CHSiMe3)(PEt3)2Cl, which exhibits superior performance compared to other analogs.
Type:
Grant
Filed:
August 9, 2022
Date of Patent:
May 9, 2023
Assignee:
THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES
Abstract: The invention provides an aqueous pharmaceutical solution for use in the treatment of diseases of the central nervous system (CNS), the solution comprising at least 5 mg/ml dissolved levodopa, and having a pH in the range of 3.0 to 8.5. Said solution is provided by mixing a) an aqueous stock solution comprising levodopa, said stock solution having a pH of less than 2.8 at 25° C. and b) an aqueous buffering solution, for increasing the pH of said stock solution, said buffering solution having a pH of at least 4.0 at 25° C. The aqueous pharmaceutical solution is administered to a subject suffering from a disease of the central nervous system (CNS) shortly after mixing of the aqueous stock solution and the aqueous buffering solution. Furthermore, the invention provides a kit for administration of aqueous pharmaceutical solutions to subjects suffering from diseases of the central nervous system (CNS).
Type:
Grant
Filed:
June 5, 2018
Date of Patent:
April 25, 2023
Assignee:
DIZLIN PHARMACEUTICALS AB
Inventors:
Elias Eriksson, Nil Dizdar Segrell, Mats Ehrnebo, Leif Bring
Abstract: Disclosed are compounds of formula (I) or a pharmaceutically acceptable salt thereof, pharmaceutical compositions containing them, and to a process for the preparation of the compounds: R1 is independently selected from hydrogen atom, amine group, monocyclic or bicyclic aliphatic, aromatic, heteroaliphatic or heteroaromatic ring. R2 is independently selected from monocyclic or bicylic aliphatic, heteroaliphatic, aromatic or heteroaromatic ring, C1-C6 alkyl, alkenyl or alkynyl chain. n is 1 or 2; preferably n is 1. m is 0, 1 or 2; preferably m is 0. R3 and R4 can be, independently, —H, —F, C1-C4 alkyl, —OH, —OC1-C4 alkyl; preferably they are both —H. X is O or S. R5 is —H or —CH3 optionally substituted by one or more fluorine atoms; preferably R5 is hydrogen. The compounds can be used in the treatment of conditions or diseases mediated by P2X7 receptor.
Type:
Grant
Filed:
May 2, 2018
Date of Patent:
April 11, 2023
Assignee:
BREYE THERAPEUTICS APS
Inventors:
Paolo Pevarello, Mariangela Sodano, Elda Severi, Rocco Vitalone, Russell Thomas, Valentina Cusano
Abstract: The present invention relates to bicyclic compounds (e.g. indoles) containing a sulfonyl moiety, which bind to the liver X receptor (LXR? and/or LXK?) and act preferably as inverse agonists of LXR.
Type:
Grant
Filed:
June 28, 2019
Date of Patent:
April 4, 2023
Assignee:
OrsoBio, Inc.
Inventors:
Christian Gege, Olaf Kinzel, Eva Hambruch, Manfred Birkel, Claus Kremoser, Ulrich Deuschle
Abstract: The present invention relates to sulfonylureas and sulfonylthioureas comprising a 5-membered nitrogen-containing heteroaryl ring attached to the sulfonyl group, wherein the heteroaryl ring is substituted with a nitrogen-containing group R1? wherein R1 contains from 1 to 7 atoms other than hydrogen or halogen. The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.
Type:
Grant
Filed:
August 15, 2018
Date of Patent:
March 28, 2023
Assignee:
Inflazome Limited
Inventors:
Matthew Cooper, David Miller, Angus Macleod, Stephen Thom, Stephen St-Gallay, Jonathan Shannon, Thomas Alanine, Stuart Onions, Ian Strutt, Jokin Carrillo Arregui
Abstract: The present disclosure relates generally to certain tricyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
Type:
Grant
Filed:
January 18, 2022
Date of Patent:
March 28, 2023
Assignee:
Gilead Sciences, Inc.
Inventors:
Hang Chu, Ana Z. Gonzalez Buenrostro, Hongyan Guo, Xiaochun Han, Anna E. Hurtley, Lan Jiang, Jiayao Li, David W. Lin, Michael L. Mitchell, Devan Naduthambi, Gregg M. Schwarzwälder, Suzanne M. Szewczyk, Matthew J. Von Bargen, Qiaoyin Wu, Hong Yang, Jennifer R. Zhang
Abstract: Provided are compounds of the Formula (I), or a pharmaceutically acceptable salt thereof: wherein W, X, Y, Z, x, R1, R2, R3, x and n are defined in the specification. The compounds are inhibitors of lysyl oxidase (LOX) and lysyl oxidase-like (LOXL) family members (LOXL1, LOXL2, LOXL3, LOXL4) and are useful in therapy, particularly in the treatment of cancer. Also disclosed are LOX inhibitors for use in the treatment of a cancer associated with EGFR and biomarkers that predict responsiveness to a LOX inhibitor.
Type:
Grant
Filed:
April 2, 2021
Date of Patent:
March 21, 2023
Assignee:
THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
Inventors:
Caroline Springer, Richard Marais, Dan Niculescu-Duvaz, Leo Leung, Deborah Smithen, Cedric Callens, Haoran Tang
Abstract: The present invention relates to synthetic receptors for ionophoric compounds, such as ionophoric toxins. Hence, the invention provides synthetic molecules capable of binding different ionophoric compounds, thereby being suitable for use in the detection, isolation and detoxification of such ionophoric compounds. The present invention further provides the use of such synthetic receptors in human and veterinary medicine, such as in the diagnosis, prevention and/or treatment of disorders caused by such ionophoric compounds. Finally, the invention provides methods of preparing such synthetic receptors for ionophoric compounds.
Type:
Grant
Filed:
February 27, 2019
Date of Patent:
March 21, 2023
Assignee:
Universiteit Gent
Inventors:
Vincent Ornelis, Annemieke Madder, Sarah de Saeger, Andreja Rajkovic, Benedikt Sas
Abstract: Described herein are small molecule splicing modulator compounds that modulate splicing of mRNA, such as pre-mRNA, encoded by genes, and methods of use of the small molecule splicing modulator compounds for modulating splicing and treating diseases and conditions.
Type:
Grant
Filed:
October 15, 2021
Date of Patent:
March 14, 2023
Assignee:
SKYHAWK THERAPEUTICS, INC.
Inventors:
Michael Luzzio, Kathleen McCarthy, William Haney
Abstract: Provided herein is an amorphous form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the amorphous form of Compound 1, described herein.
Type:
Grant
Filed:
November 6, 2020
Date of Patent:
March 14, 2023
Assignee:
CHEMOCENTRYX, INC.
Inventors:
Kwok Yau, Kenken Luong, Rajinder Singh, Yibin Zeng, Penglie Zhang, Manmohan Reddy Leleti, Rebecca M. Lui
Abstract: The invention encompasses ex vivo method of stimulating isolated memory T-cell, tumor-infiltrating lymphocyte (TIL), T cell receptor (TCR) engineered cell, and/or chimeric antigen receptor (CAR) engineered cell with compounds of Formula I below, which are inhibitors of the TC-PTP enzyme.
Type:
Grant
Filed:
August 24, 2018
Date of Patent:
March 7, 2023
Assignee:
THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
Inventors:
Michel L. Tremblay, Kelly-Anne Pike, Luis Alberto Perez Quintero
Abstract: Realized is a method for restoring the activity of a catalyst for producing a carbonate ester by a simple technique with no use of a complicated step such as calcining or the like to allow the catalyst to be reusable, and a method for producing a carbonate ester at a high yield by use of the catalyst thus regenerated. The above-described problem has been solved by a method for regenerating a catalyst containing CeO2, the catalyst being usable for a carbonate ester generation reaction of generating a carbonate ester from carbon dioxide and an alcohol, the method comprising (a) a separation step of separating the catalyst as a crude catalyst from a reaction solution of carbon dioxide and the alcohol; and (b) a catalyst processing step of washing the crude catalyst with a washing alcohol to provide a purified catalyst.